Rate of natural disease progression in patients with chronic hepatitis C. (Q44314893)

1 December 2017

Rate of natural disease progression in patients with chronic hepatitis C. (English)

1 reference

1 December 2017

1 reference

1

Jean-Pierre Zarski

0 references

author name string

Jean-Pierre Zarski

1

1 reference

1 December 2017

John Mc Hutchison

2

1 reference

1 December 2017

Jean-Pierre Bronowicki

3

1 reference

1 December 2017

Nathalie Sturm

4

1 reference

1 December 2017

Richard Garcia-Kennedy

5

1 reference

1 December 2017

Enkelejda Hodaj

6

1 reference

1 December 2017

Brenda Truta

7

1 reference

1 December 2017

Teresa Wright

8

1 reference

1 December 2017

Robert Gish

9

1 reference

1 December 2017

1 March 2003

1 reference

1 December 2017

Journal of Hepatology

1 reference

1 December 2017

38

1 reference

1 December 2017

3

1 reference

1 December 2017

307-314

1 reference

Natural history of hepatitis C.

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Modeling the hepatitis C virus epidemic in France

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C--a study of 527 patients at one establishment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Natural history of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Natural history of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

The influence of host factors on the natural history of chronic hepatitis C viral infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Importance of age in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Histological features predictive of liver fibrosis in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900387-2

7 January 2021

10.1016/S0168-8278(02)00387-2

Identifiers

DOI

1 reference

1 December 2017

1 reference